TAKOMA PARK, Md.--(BUSINESS WIRE)--On September 18, 2013, a surgical team at Temple University Hospital, Philadelphia, Pa., performed a groundbreaking procedure on a patient who had previously been diagnosed with inoperable metastatic Stage 4 Breast cancer, using the Canady Vieira Hybrid Plasma™ (CVHP) Scalpel developed and sold by US Medical Innovations, LLC (USMI). The CVHP™ Scalpel is an advanced electrosurgical plasma device utilizing Hybrid Plasma Technology, which is a revolutionary patent pending energy beam that simultaneously cuts and coagulates biological tissues.
The multidisciplinary team of doctors and scientists from multiple medical centers collaborated over a nine-month period to design a treatment plan consisting of preoperative chemo and radiation therapy, along with computerized mapping of the surgical procedure via the CT scan. “We are extremely excited about the outcome for this patient. The treatment plan, led by Victor Priego, M.D. and myself, involving this phenomenal team of doctors, resulted in a curative resection,” stated Jerome Canady, M.D.
After successful cytoreduction (shrinkage) of the tumor from the breast, chest wall and liver, staged surgical procedures were performed. The breast tumor was removed in July of 2013 by Robert Dewitty, M.D., surgical oncologist at Providence Hospital, Washington, DC. In September of 2013, Andreas Karachristos, M.D., Ph.D., Chief of Hepatobiliary Surgery, and Abbas El-Sayeh Abbas, M.D., Chief of Thoracic Surgery successfully removed the tumor from the chest wall and liver at Temple University Hospital, in Philadelphia, Pa.
US Medical Innovations, LLC (USMI), a subsidiary of US Patent Innovations, LLC, is a private US biomedical device specification manufacturing, research and development company, focusing on the advancement of innovative and affordable plasma electrosurgical devices.